Valneva SE (VALN) Non-Current Deffered Revenue (2021 - 2026)
Valneva SE's (VALN) quarterly Non-Current Deffered Revenue came in at $499908.4 in Q1 2026, down 87.33% year-on-year from $3.9 million in Q1 2025, and down 0.59% quarter-over-quarter from $502866.8 in Q4 2025.
Valneva SE (VALN) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Non-Current Deffered Revenue across 6 years of filings, most recently posting $499908.4 for Q1 2026.
- Non-Current Deffered Revenue for Q1 2026 came in at $499908.4, down 87.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $499908.4 (down 87.33% YoY), and the FY2025 annual result was $502866.8, down 84.37% from the prior year.
- Non-Current Deffered Revenue came in at $499908.4 for Q1 2026 at Valneva SE, down from $502866.8 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $137.5 million in Q1 2022 to a low of $494510.3 in Q3 2025.
- The 5-year median for Non-Current Deffered Revenue is $5.7 million (2024), against an average of $20.4 million.
- Peak annual rise in Non-Current Deffered Revenue reached 108.6% in 2023, while the deepest fall reached 92.85% in 2023.
- Valneva SE's Non-Current Deffered Revenue stood at $9.6 million in 2022, then sank by 36.16% to $6.1 million in 2023, then slumped by 47.53% to $3.2 million in 2024, then tumbled by 84.37% to $502866.8 in 2025, then decreased by 0.59% to $499908.4 in 2026.
- The last three Non-Current Deffered Revenue figures came in at $499908.4 (Q1 2026), $502866.8 (Q4 2025), and $494510.3 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | 499,908.39 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 499,908.39 |
| Dec 31, 2025 | 502,866.80 |
| Sep 30, 2025 | 494,510.30 |
| Jun 30, 2025 | 588,619.04 |
| Mar 31, 2025 | 3.95 Mn |
| Dec 31, 2024 | 3.22 Mn |
| Sep 30, 2024 | 1.05 Mn |
| Jun 30, 2024 | 5.71 Mn |
| Mar 31, 2024 | 5.75 Mn |
| Dec 31, 2023 | 6.13 Mn |
| Sep 30, 2023 | 14.53 Mn |
| Jun 30, 2023 | 12.61 Mn |
| Mar 31, 2023 | 9.83 Mn |
| Dec 31, 2022 | 9.60 Mn |
| Sep 30, 2022 | 6.96 Mn |
| Jun 30, 2022 | 127.74 Mn |
| Mar 31, 2022 | 137.46 Mn |
| Dec 31, 2021 | 5.42 Mn |